share_log

BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25

BMO Capital Maintains Market Perform on CytomX Therapeutics, Lowers Price Target to $3.25

BMO Capital维持CytomX Therapeutics的市场表现,将目标股价下调至3.25美元
Moomoo 24/7 ·  03/12 11:11

BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and lowers the price target from $3.3 to $3.25.

BMO Capital分析师埃策·达鲁特维持CytomX Therapeutics(纳斯达克股票代码:CTMX)的市场表现,并将目标股价从3.3美元下调至3.25美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发